Literature DB >> 31552470

Resolution of Crohn's disease.

Heike Schmitt1, Clemens Neufert1, Markus F Neurath1, Raja Atreya2.   

Abstract

Crohn's disease (CD) is characterized by chronic inflammation of the gastrointestinal tract and represents one of the main inflammatory bowel disease (IBD) forms. The infiltration of immune cells into the mucosa and uncontrolled production of pro-inflammatory cytokines and other mediators trigger the chronic inflammatory reaction in the intestine [1]. The inflammatory setting consists of subsequent events that comprise an induction phase, the peak of inflammation which is subsequently followed by the resolution phase. The induction phase, which represents the first phase of inflammation, is important for the rapid and efficient activation of the immune system for sufficient host defense. The permanent sensing of exogenous or endogenous danger signals enables the fast initiation of the inflammatory reaction. The immune cell infiltrate initiates an inflammatory cascade where released lipid and protein mediators play an indispensable role [2, 3]. The last decades of research strongly suggest that resolution of inflammation is similarly a tightly coordinated and active process. The basic concept that resolution of inflammation has to be regarded as an active process has been thoroughly described by others [4-6]. The following review focuses on mechanisms, pathways, and specific mediators that are actively involved in the resolution of inflammation in CD.

Entities:  

Keywords:  Anti-TNF therapy; Apoptosis; Crohn’s disease; IL23; Intestine; Resolution of inflammation

Mesh:

Substances:

Year:  2019        PMID: 31552470     DOI: 10.1007/s00281-019-00756-1

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  112 in total

1.  Immunogenicity to infliximab is associated with HLA-DRB1.

Authors:  Thomas Billiet; Niels Vande Casteele; Thomas Van Stappen; Fred Princen; Sharat Singh; Ann Gils; Marc Ferrante; Gert Van Assche; Isabelle Cleynen; Severine Vermeire
Journal:  Gut       Date:  2015-04-15       Impact factor: 23.059

Review 2.  IBD pathogenesis in 2014: Molecular pathways controlling barrier function in IBD.

Authors:  Raja Atreya; Markus F Neurath
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-12-02       Impact factor: 46.802

Review 3.  The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution.

Authors:  Charles N Serhan; Nan Chiang; Jesmond Dalli
Journal:  Semin Immunol       Date:  2015-04-07       Impact factor: 11.130

4.  IL-10 therapy in Crohn's disease: at the crossroads. Treatment of Crohn's disease with the anti-inflammatory cytokine interleukin 10.

Authors:  H Herfarth; J Schölmerich
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

Review 5.  The fundamental basis of inflammatory bowel disease.

Authors:  Warren Strober; Ivan Fuss; Peter Mannon
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 6.  Healing of intestinal inflammation by IL-22.

Authors:  Atsushi Mizoguchi
Journal:  Inflamm Bowel Dis       Date:  2012-02-22       Impact factor: 5.325

Review 7.  The Dynamics of Apoptotic Cell Clearance.

Authors:  Michael R Elliott; Kodi S Ravichandran
Journal:  Dev Cell       Date:  2016-07-25       Impact factor: 12.270

Review 8.  Therapeutic opportunities of the IL-22-IL-22R1 system.

Authors:  Robert Sabat; Wenjun Ouyang; Kerstin Wolk
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

9.  Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease.

Authors:  Kelly A Shaw; Madeline Bertha; Tatyana Hofmekler; Pankaj Chopra; Tommi Vatanen; Abhiram Srivatsa; Jarod Prince; Archana Kumar; Cary Sauer; Michael E Zwick; Glen A Satten; Aleksandar D Kostic; Jennifer G Mulle; Ramnik J Xavier; Subra Kugathasan
Journal:  Genome Med       Date:  2016-07-13       Impact factor: 11.117

10.  Fungal microbiota dysbiosis in IBD.

Authors:  Harry Sokol; Valentin Leducq; Hugues Aschard; Hang-Phuong Pham; Sarah Jegou; Cecilia Landman; David Cohen; Giuseppina Liguori; Anne Bourrier; Isabelle Nion-Larmurier; Jacques Cosnes; Philippe Seksik; Philippe Langella; David Skurnik; Mathias L Richard; Laurent Beaugerie
Journal:  Gut       Date:  2016-02-03       Impact factor: 23.059

View more
  10 in total

1.  Resolution of inflammation: from basic concepts to clinical application.

Authors:  Markus F Neurath
Journal:  Semin Immunopathol       Date:  2019-11       Impact factor: 9.623

2.  Probiotic Lactobacilli Isolated from Kefir Promote Down-Regulation of Inflammatory Lamina Propria T Cells from Patients with Active IBD.

Authors:  Renata Curciarello; Karina E Canziani; Ileana Salto; Emanuel Barbiera Romero; Andrés Rocca; Ivan Doldan; Emmanuel Peton; Santiago Brayer; Alicia M Sambuelli; Silvina Goncalves; Pablo Tirado; Gustavo J Correa; Martín Yantorno; Laura Garbi; Guillermo H Docena; María de Los Ángeles Serradell; Cecilia I Muglia
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 3.  Role of the IL23/IL17 Pathway in Crohn's Disease.

Authors:  Heike Schmitt; Markus F Neurath; Raja Atreya
Journal:  Front Immunol       Date:  2021-03-30       Impact factor: 7.561

Review 4.  IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality.

Authors:  Raja Atreya; Markus F Neurath
Journal:  J Crohns Colitis       Date:  2022-05-11       Impact factor: 10.020

5.  Untargeted serum metabolomics reveals specific metabolite abnormalities in patients with Crohn's disease.

Authors:  Huanhuan Liu; Minmin Xu; Qiongzi He; Peng Wei; Mengying Ke; Shijia Liu
Journal:  Front Med (Lausanne)       Date:  2022-09-08

6.  Fibrin(ogen) Is Constitutively Expressed by Differentiated Intestinal Epithelial Cells and Mediates Wound Healing.

Authors:  Amira Seltana; Gabriel Cloutier; Vilcy Reyes Nicolas; Taoufik Khalfaoui; Inga C Teller; Nathalie Perreault; Jean-François Beaulieu
Journal:  Front Immunol       Date:  2022-06-22       Impact factor: 8.786

7.  Antagonism of Adherent Invasive E. coli LF82 With Human α-defensin 5 in the Follicle-associated Epithelium of Patients With Ileal Crohn's Disease.

Authors:  Lina Y Alkaissi; Martin E Winberg; Stéphanie D S Heil; Staffan Haapaniemi; Pär Myrelid; Eduard F Stange; Johan D Söderholm; Åsa V Keita
Journal:  Inflamm Bowel Dis       Date:  2021-06-15       Impact factor: 5.325

8.  Mycobacterial Hsp65 antigen delivered by invasive Lactococcus lactis reduces intestinal inflammation and fibrosis in TNBS-induced chronic colitis model.

Authors:  Vanessa Pecini da Cunha; Tatiane Melo Preisser; Mariana Passos Santana; Denise Carmona Cara Machado; Vanessa Bastos Pereira; Anderson Miyoshi
Journal:  Sci Rep       Date:  2020-11-18       Impact factor: 4.379

9.  Computational analysis of eugenol inhibitory activity in lipoxygenase and cyclooxygenase pathways.

Authors:  Francisco das Chagas Pereira de Andrade; Anderson Nogueira Mendes
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

10.  Expression of inflammatory mediators in biofilm samples and clinical association in inflammatory bowel disease patients-a preliminary study.

Authors:  Mayte Buchbender; Jakob Fehlhofer; Peter Proff; Tobias Möst; Jutta Ries; Matthias Hannig; Markus F Neurath; Madline Gund; Raja Atreya; Marco Kesting
Journal:  Clin Oral Investig       Date:  2021-08-12       Impact factor: 3.573

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.